BIOCYTOGEN-B (02315) Rises Nearly 7% Again, Completes Localized Deployment of AI-Driven Antibody Drug R&D Platform

Stock News01-21

BIOCYTOGEN-B (02315) rose nearly 7% again. At the time of writing, the stock was up 5.08%, trading at HK$39.72, with a turnover of HK$28.32 million. On the news front, BIOCYTOGEN recently stated on an interactive platform that the company has completed the localized deployment of its AI-driven antibody drug research and development platform and has achieved full integration with its core initiative, the "Thousand Mice Ten Thousand Antibodies" project. Through the localized AI deployment, the company is currently developing an AI agent for antibody drug R&D. As the deep integration between the "Thousand Mice Ten Thousand Antibodies" project and the AI system continues to advance, the company will provide global pharmaceutical companies with more efficient R&D tools and a more extensive library of antibody molecules. This will help partner pharmaceutical companies improve the efficiency of preclinical PCC (Pharmacological and Chemical Characterization) molecule development, thereby propelling the antibody discovery business into a new phase of growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111705341?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-21 10:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111705341","market":"sg","top_or_hot":-1,"title":"BIOCYTOGEN-B (02315) Rises Nearly 7% Again, Completes Localized Deployment of AI-Driven Antibody Drug R&D Platform","media":"Stock News","content":"<p>BIOCYTOGEN-B (02315) rose nearly 7% again. At the time of writing, the stock was up 5.08%, trading at HK$39.72, with a turnover of HK$28.32 million. On the news front, BIOCYTOGEN recently stated on an interactive platform that the company has completed the localized deployment of its AI-driven antibody drug research and development platform and has achieved full integration with its core initiative, the \"Thousand Mice Ten Thousand Antibodies\" project. Through the localized AI deployment, the company is currently developing an AI agent for antibody drug R&D. As the deep integration between the \"Thousand Mice Ten Thousand Antibodies\" project and the AI system continues to advance, the company will provide global pharmaceutical companies with more efficient R&D tools and a more extensive library of antibody molecules. This will help partner pharmaceutical companies improve the efficiency of preclinical PCC (Pharmacological and Chemical Characterization) molecule development, thereby propelling the antibody discovery business into a new phase of growth.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOCYTOGEN-B (02315) Rises Nearly 7% Again, Completes Localized Deployment of AI-Driven Antibody Drug R&D Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOCYTOGEN-B (02315) Rises Nearly 7% Again, Completes Localized Deployment of AI-Driven Antibody Drug R&D Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-21 10:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BIOCYTOGEN-B (02315) rose nearly 7% again. At the time of writing, the stock was up 5.08%, trading at HK$39.72, with a turnover of HK$28.32 million. On the news front, BIOCYTOGEN recently stated on an interactive platform that the company has completed the localized deployment of its AI-driven antibody drug research and development platform and has achieved full integration with its core initiative, the \"Thousand Mice Ten Thousand Antibodies\" project. Through the localized AI deployment, the company is currently developing an AI agent for antibody drug R&D. As the deep integration between the \"Thousand Mice Ten Thousand Antibodies\" project and the AI system continues to advance, the company will provide global pharmaceutical companies with more efficient R&D tools and a more extensive library of antibody molecules. This will help partner pharmaceutical companies improve the efficiency of preclinical PCC (Pharmacological and Chemical Characterization) molecule development, thereby propelling the antibody discovery business into a new phase of growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0216","symbol_name":"研究试验","start_time":0,"source_url":"","article_id":"1111705341","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111705341","pubTimestamp":1768962616,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BIOCYTOGEN-B (02315) rose nearly 7% again. At the time of writing, the stock was up 5.08%, trading at HK$39.72, with a turnover of HK$28.32 million. On the news front, BIOCYTOGEN recently stated on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688796":"百奥赛图","BK0216":"研究试验","02800":"盈富基金","BK1610":"ETF&股票定投概念","BK1161":"生物科技","02315":"百奥赛图-B"},"translate_title":"百奥赛图-B(02315)再涨近7%，完成AI驱动抗体药物研发平台本土化部署","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688796":1,"02315":1,"02800":1},"content_text":"BIOCYTOGEN-B (02315) rose nearly 7% again. At the time of writing, the stock was up 5.08%, trading at HK$39.72, with a turnover of HK$28.32 million. On the news front, BIOCYTOGEN recently stated on an interactive platform that the company has completed the localized deployment of its AI-driven antibody drug research and development platform and has achieved full integration with its core initiative, the \"Thousand Mice Ten Thousand Antibodies\" project. Through the localized AI deployment, the company is currently developing an AI agent for antibody drug R&D. As the deep integration between the \"Thousand Mice Ten Thousand Antibodies\" project and the AI system continues to advance, the company will provide global pharmaceutical companies with more efficient R&D tools and a more extensive library of antibody molecules. This will help partner pharmaceutical companies improve the efficiency of preclinical PCC (Pharmacological and Chemical Characterization) molecule development, thereby propelling the antibody discovery business into a new phase of growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111705341","isCrawlerRequest":true}